ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "prognostic factors"

  • Abstract Number: 1428 • ACR Convergence 2022

    Molecular and Clinical Profiling of Rheumatoid Arthritis Patients Predicts the Response to Rituximab

    Daniel Toro-Domínguez1, José Linares-Blanco1, Raúl López-Domínguez2, Pilar S. López-Garrido2, Georgina Galicia-Rosas1, Pedro Carmona-Sáez2 and Marta Alarcon-Riquelme1, 1Center for Genomics and Oncological Research (GENYO), Granada, Spain, 2University of Granada, Granada, Spain

    Background/Purpose: Rheumatoid arthritis (RA) is one of the most prevalent rheumatic diseases, mainly characterized by chronically painful, swollen joints that can severely impair physical function…
  • Abstract Number: 0533 • ACR Convergence 2022

    Sputum RA-Associated Autoantibodies Independently Associate with Future Development of Classified RA in an At-Risk Cohort of Individuals with Systemic Anti-CCP Positivity

    Timothy Wilson1, Jacob Welch2, Marie Feser2, Elizabeth Bemis2, Claudia Lugo2, Gary S. Firestein3, Thomas F. Bumol4, Jill Norris5, V. Michael Holers6, Kevin D Deane7 and Kristen Demoruelle2, 1University of Colorado Denver Anschutz Medical Campus, Aurora, CO, 2University of Colorado Anschutz Medical Campus, Aurora, CO, 3University of California, San Diego, San Diego, CA, 4Allen Institute for Immunology, Seattle, WA, 5Colorado School of Public Health, Aurora, CO, 6University of Colorado, Denver, CO, 7University of Colorado Denver Anschutz Medical Campus, Denver, CO

    Background/Purpose: Presence of systemic anti-CCP-IgG antibodies in individuals without inflammatory arthritis (IA) strongly predicts developing future classified RA. However, published data also demonstrate that 50-70%…
  • Abstract Number: 1436 • ACR Convergence 2022

    Predictors at Diagnosis for Start of Biologic Disease Modifying Anti-Rheumatic Drugs in Patients with Early Rheumatoid Arthritis

    Mohaned Hameed1, Sofia Exarchou1, Anna Eberhard1, Ankita Sharma1, Ulf Bergström1, Jon Einarsson2 and Carl Turesson3, 1Lund University, Malmö, Sweden, 2Skåne University Hospital, Lund, Sweden, 3Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden

    Background/Purpose: With increasing use of biologic disease modifying anti-rheumatic drugs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs) for the management of rheumatoid arthritis (RA), outcomes have…
  • Abstract Number: 0537 • ACR Convergence 2022

    Neutrophil Extracellular Traps as a Biomarker to Predict Outcomes in Lupus Nephritis

    Laura Patricia Whittall Garcia1, Farnoosh Naderinavi1, Zahi Touma2, Dafna Gladman3, Murray Urowitz4, Anna Konvalinka1 and Joan Wither5, 1University Health Network, Toronto, ON, Canada, 2Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, 3Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, 4University of Toronto, University Health Network, Schroeder Arthritis Institute, Toronto, ON, Canada, 5Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, University of Toronto, Toronto, ON, Canada

    Background/Purpose: Neutrophil Extracellular Traps (NETs) have been implicated in Lupus Nephritis (LN) pathogenesis. SLE neutrophils release High Mobility Group Box-1 (HMGB1) protein, in turn, HMGB1…
  • Abstract Number: 1443 • ACR Convergence 2022

    Lymphadenopathy in Systemic Lupus Erythematosus: Clinical Characteristics and Prognostic Features

    Eleni Papachristodoulou, Daniel Magliulo and Vasileios Kyttaris, Beth Israel Deaconess Medical Center, Boston, MA

    Background/Purpose: Patients with SLE often develop lymphadenopathy (LAD), regarded as a relatively common manifestation of the disease. Its clinical significance has not yet been elucidated.…
  • Abstract Number: 0672 • ACR Convergence 2022

    Immune Thrombocytopenia Could Be an Independent Phenotype of Primary Antiphospholipid Syndrome

    Yu Shi1, Jiuliang Zhao2 and Xiaofeng Zeng2, 1Chinese Academy of Medical Sciences, Peking Union Medical College, Dongcheng Qu, China, 2Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China

    Background/Purpose: Among patients with immune thrombocytopenia (ITP), 10-30% of them were found with positive antiphospholipid antibodies (aPLs) but without typical clinical manifestations of antiphospholipid syndrome…
  • Abstract Number: 1455 • ACR Convergence 2022

    Immune Thrombocytopenic Purpura and Subsequent Development of Systemic Lupus Erythematosus

    Gelsomina Alle1, Marina Scolnik1, VALERIA SCAGLIONI1, John Fredy Jaramillo Gallego1, Mayra Alejandra Tobar Jaramillo1, Rodolfo Alvarado1, Enrique R Soriano2 and Javier Eduardo Rosa1, 1Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 2Rheumatology Unit and University Institute, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina

    Background/Purpose: The aim of this study is to assess the incidence of Systemic Lupus Erythematosus (SLE) in a cohort of patients with Immune Thrombocytopenic Purpura…
  • Abstract Number: 0676 • ACR Convergence 2022

    Presentation and Outcomes in Patients with Adrenal Hemorrhage Associated with Antiphospholipid Syndrome: A Cohort Study and Systematic Review of Literature

    Jose A Meade-Aguilar1, Gabriel Figueroa Parra1, Jeffrey X. Yang1, Hannah Langenfeld2, Prerna Dogra1, Irina Bancos3, Hassan Murad3, Cynthia Crowson4 and Ali Duarte-Garcia1, 1Mayo Clinic, Rochester, MN, 2Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, 3Mayo Clinic, Rochester, 4Mayo Clinic, Eyota, MN

    Background/Purpose: To describe the clinical characteristics, therapies, and outcomes of patients with antiphospholipid syndrome (APS) and adrenal hemorrhage (AH).Methods: We performed a multicenter retrospective cohort…
  • Abstract Number: 1524 • ACR Convergence 2022

    Risk Factors for Lung Function Decline in Systemic Sclerosis Interstitial Lung Disease in a Large Single-Center Cohort

    Ahmad Ramahi1, Alain Lescoat2, David Roofeh1, Vivek Nagaraja1, Rajaie Namas3, Suiyuan Huang1, John Varga1, David O’Dwyer1, Bonnie Wang1, Kevin Flaherty1, Ella Kazerooni1 and Dinesh Khanna4, 1University of Michigan, Ann Arbor, MI, 2CHU Rennes - University Rennes 1, Rennes, France, 3Medical Subspecialties Institute, Division of Rheumatology at Cleveland Clinic, Abu Dhabi, United Arab Emirates, 4Division of Rheumatology, Department of Internal Medicine, Scleroderma Program, University of Michigan, Ann Arbor, MI

    Background/Purpose: Systemic sclerosis-associated interstitial lung disease (SSc-ILD) is the leading cause of scleroderma-related mortality. This work identifies factors associated with SSc-ILD decline on pulmonary function…
  • Abstract Number: 0083 • ACR Convergence 2021

    Cardiac Valve Surgery Outcomes in the Antiphospholipid Syndrome

    Tali Eviatar1, Stanley Niznik2, Nancy Agmon-Levin2 and Daphna Paran3, 1Tel Aviv Sourasky Medical Center, Givataim, Israel, 2Sheba Medical Center, Ramat Gan, Israel, 3Tel Aviv Sourasky Medical Center-Ichilov Hospital, Even Yehuda, Israel

    Background/Purpose: Cardiac valve involvement in the APS is prevalent, necessitating valve surgery in about 5% of the patients. Data regarding valve surgery outcomes in APS…
  • Abstract Number: 1834 • ACR Convergence 2021

    To What Extent Do Clinical Features of PsA Predict Achievement of Minimal Disease Activity at Week 24: A Post Hoc Analysis of the Phase III Clinical Trial Program of Guselkumab in a Bio-naïve Patient Population

    Marijn Vis1, Pascal Richette2, Ramirez Julio3, Marlies Neuhold4, Robert Wapenaar5, Elke Theander6, Wim Noel7, May Shawi8, Alexa Kollmeier9 and William Tillett10, 1Erasmus MC, Badhoevedorp, Netherlands, 2Lariboisiere Hospital, Paris, France, 3Hospital Universitari Clinic, Barcelona, Spain, 4Janssen-Cilag, Zug, Switzerland, 5Janssen-Cilag BV, Breda, Netherlands, 6Janssen Cilag, Lund, Sweden, 7Janssen Pharmaceutica, Vilvoorde, Belgium, 8Janssen Immunology Global Commercial Strategy Organization, Toronto, ON, Canada, 9Janssen Research & Development, LLC, La Jolla, CA, 10Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom

    Background/Purpose: Guselkumab (GUS), a human monoclonal antibody targeting the interleukin-23p19-subunit, has demonstrated efficacy across joint and skin endpoints at Week 24 (W24) in the Phase…
  • Abstract Number: 0254 • ACR Convergence 2021

    Patient and Disease-Level Factors Associated with Sustained Cessation of Medication for Disease Remission in Systemic Juvenile Idiopathic Arthritis

    Elaine Flanagan1, Rosemary Peterson2, Susan Shenoi3, Helena Chang4, Kelly Wang4, Rebecca Trachtman4 and Karen Onel5, 1Emory/CHOA, Atlanta, GA, 2Dell Children's Medical Center, Austin, TX, 3Seattle Children's Hospital, Seattle, WA, 4Icahn School of Medicine at Mount Sinai, New York, NY, 5Hospital for Special Surgery, New York, NY

    Background/Purpose: The emergence of IL-1 and IL-6 inhibitors (biologics) for the treatment of systemic juvenile idiopathic arthritis (SJIA) has dramatically improved patient outcomes. With higher…
  • Abstract Number: 1848 • ACR Convergence 2021

    Untangling the Gut: A Phenome-Wide Association Study of Drugs and Diseases with Gastrointestinal Dysfunction in Systemic Sclerosis

    Rory Maclean1, Fiza Ahmed2, Voon Ong3, Charles Murray4 and Christopher Denton5, 1Royal Free Hospital & University College London, London, United Kingdom, 2Royal Free Hospital, Ilford, United Kingdom, 3University College London Medical School Royal Free Campus, London, United Kingdom, 4Royal Free Hospital, London, United Kingdom, 5University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, United Kingdom

    Background/Purpose: Gastrointestinal dysfunction (SSc-GI) is a significant burden to patients with systemic sclerosis (SSc), particularly in those with longstanding disease. The management of SSc-GI is…
  • Abstract Number: 0344 • ACR Convergence 2021

    Anti-gAChR Antibody as a Novel Biomarker for Lupus Enteritis in Systemic Lupus Erythematosus

    Kuniyuki Aso1, Michihito Kono1, Keita Ninagawa1, Nobuya Abe1, Yuichiro Fujieda1, Masaru Kato1, Olga Amengual1, Kenji Oku1 and Tatsuya Atsumi2, 1Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, 2Hokkaido University, Sapporo, Japan

    Background/Purpose: Anti-ganglionic nicotinic acetylcholine receptor (gAChR) antibody (Ab) is associated with widespread autonomic dysfunction in autoimmune autonomic ganglionopathy. Although it is also detected in several…
  • Abstract Number: 0388 • ACR Convergence 2021

    Prediction Tool for Damage Accrual Trajectory in Incident Systemic Sclerosis

    Ariane Barbacki1, Ada Man2, Mianbo Wang3, Dylan Johnson4, Yuqing Zhang5, Mandana Nikpour6 and Murray Baron7, 1McGill University, Montral, Montréal, QC, Canada, 2University of Manitoba, Winnipeg, MB, Canada, 3Lady Davis institute for Medical Research, Montréal, QC, Canada, 4University of Alberta, Edmonton, AB, Canada, 5Massachusetts General Hospital, Quincy, MA, 6University of Melbourne at St Vincent's Hospital, Melbourne, Australia, 7Jewish General Hospital, Montréal, QC, Canada

    Background/Purpose: Systemic sclerosis (SSc) is a systemic autoimmune disease associated with the accrual of organ damage over time, which can be measured using the Scleroderma…
  • « Previous Page
  • 1
  • …
  • 8
  • 9
  • 10
  • 11
  • 12
  • …
  • 18
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology